Lithium treatment

DRUG3 trials

Sponsors

VA Office of Research and Development, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Universitaire Dijon

Conditions

Bipolar DisorderBipolar I DisorderProven Pathogenic or Probably Pathogenic TBR1 Variant

Phase 1

A Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With TBR1-related Neurocognitive Disorder

RecruitingNCT06776848

Centre Hospitalier Universitaire DijonProven Pathogenic or Probably Pathogenic TBR1 Variant

Start: 2025-09-12End: 2027-09-12Target: 12Updated: 2026-05-22

Unknown Phase

Genetic Predictors of Lithium Response in Bipolar Disorder

CompletedNCT00252577

VA Office of Research and DevelopmentBipolar Disorder

Start: 2005-10-31End: 2016-05-31Updated: 2020-01-29

Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative

Assistance Publique - Hôpitaux de ParisBipolar I Disorder

Start: 2020-01-10End: 2024-06-30Target: 320Updated: 2022-07-13